Eli Lilly and Company (LLY) Gains Approval in Australia for Early Alzheimer's Treatment
Eli Lilly and Company (NYSE:LLY) recently announced that Australia's Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous infusion every four weeks, is intended to treat adults with mild cognitive impairment or mild dementia caused by Alzheimer's disease, specifically those who are either non-carriers or have a single ApoE ε4 gene.
Kisunla stands out as the first amyloid-targeting Alzheimer's therapy approved in Australia. It's also the only treatment of its kind supported by clinical evidence, allowing patients to stop treatment once amyloid plaques are cleared.
However, medical experts have noted that fewer than 20% of dementia patients are likely to qualify for the therapy, which may cost patients over $80,000 out of pocket.
Professor Christopher Rowe, head of the Australian Dementia Network, emphasized the significance of the approval, noting that it's the first Alzheimer's treatment in 25 years to impact disease progression. While older medications only temporarily eased symptoms, Kisunla has shown it can slow cognitive decline by roughly 33%.
That said, the drug comes with risks. It has been linked to brain swelling and bleeding, particularly in individuals carrying two ApoE ε4 genes.
According to Eli Lilly and Company (NYSE:LLY)'s release, around 600,000 Australians are currently living with Alzheimer's, with about 450,000 in the early stages who might be evaluated for Kisunla treatment. Alzheimer's remains the third leading cause of death in the country.
While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.
READ MORE: and
Disclosure. None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Decatur Police use radio transmitting bracelet to locate lost or missing individuals
DECATUR, Ala. (WHNT) — The Decatur Police Department wants to remind the community of a resource they offer, known as Project Lifesaver. It's a search and rescue program targeted for individuals who have cognitive disorders such as Autism and Alzheimer's that may be prone to wander or get lost. Opening statements begin in trial of Decatur chiropractor charged with attempted murder of wife Decatur Police said the bracelet works through radio frequencies. 'The bracelets have radio transmitters in them, so in the event they get separated from their family, they transmit a radio frequency, and that just really closes in on the amount of time it takes to find them,' Irene Cardenas Martinez said. Martinez is the Public Information Liaison for the Decatur Police Department. When a client signs up for the program, they are given a radio frequency tracking number. That number sits inside the bracelet and inside their computer system. To qualify, they say an individual must: Have a caregiver with them at least 75% of the time. Wear the bracelet at all times. Never drive a vehicle at any time. If an individual is lost, they can enter that number into the Project Lifesaver device, and it tells them where they are located. DPD said there is no cost to enroll in the bracelet department. For more information to see if you or a loved one qualifies, you can call (256) 341-4600 or visit the Police Department's front desk. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
29 minutes ago
- Yahoo
Sen. Collins grills NIH director on research cuts
Jun. 10—Dr. Jay Bhattacharya, the new director of the National Institutes of Health, faced sharp questions from Sen. Susan Collins and other senators Tuesday about a proposed 40% budget reduction at the NIH and other cutbacks that are disrupting biomedical research. Bhattacharya appeared before the Senate Appropriations Committee's subcommittee on labor, health and human services and education on Tuesday as the Trump administration has slashed funding for biomedical research and public health. On Monday, hundreds of NIH scientists signed a letter, called the "Bethesda Declaration," asking the Trump administration to protect funding for biomedical research. Also Monday, Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns among public health advocates when he summarily dismissed all 17 members of a key committee that advises the government on approving vaccines. Kennedy, who has falsely questioned the safety and efficacy of vaccines, has not said who he would place on the Advisory Committee on Immunization Practices, which among other duties, recommends the formulation for the annual influenza vaccine. At the Senate hearing Tuesday, Bhattacharya largely dodged questions about the Trump administration's proposals to slash the agency, and the ongoing cuts to research grants. Collins, who voted to confirm Bhattacharya but has decried NIH cuts, questioned why the Trump administration is requesting a $19 billion cut to the NIH in the 2026 budget, which she said would "undo years of congressional investment." "It would delay or stop effective treatments and cures being developed for diseases like Alzheimer's, cancer and Type 1 diabetes," said Collins, who is chair of the Appropriations Committee. "We also risk falling behind China and other countries that are increasing their investment in biomedical research." Bhattacharya said the agency is "fully committed" to making progress on Alzheimer's and that the 2026 budget will be a "collaboration" between Congress and the White House. But, despite getting a series of questions from Collins and other Republican and Democratic senators, Bhattacharya did not specifically address the rationale for the budget cuts. Collins has also been speaking out for months against the agency's moves to cap the amount of money that biomedical researchers can use for indirect costs at no more than 15% of their NIH grants. The indirect costs include overhead expenses, equipment and technical support for scientific research and scientists say the cap would hobble research laboratories in Maine and across the country. The amount that NIH grants pay for indirect costs varies by grant, but made up 26% of the cost of each grant, on average, in 2023. Collins has also directly lobbied Kennedy to reverse the NIH cap on indirect costs, and Maine has joined other states in a lawsuit to block the cuts. On Tuesday, Collins said she is still "alarmed and surprised the administration's budget request (for next year) contains the same 15% cap." Bhattacharya said he couldn't discuss the indirect costs issue because of the pending lawsuit, but that there's "lots of great possibilities for reform" on how NIH awards grants for research. Sen. Tammy Baldwin, D-Wisconsin, also pointed out that the NIH has so far in 2025 spent $3 billion less on biomedical research compared to the same time in 2024, largely by freezing or denying grant funding on research that Congress previously approved. Much of the denied funding is the subject of pending lawsuits by states and universities that argue the Trump administration is illegally blocking the funding. The lawsuits argue that the executive branch is required to spend money that Congress approves, and the Trump administration does not have the power to block previously approved funding. "How is this anything other than sabotaging biomedical research?" Baldwin said. Bhattacharya did not answer, except to say he's "happy to work with Congress" on funding issues. Sen. Richard Durbin, D-Illinois, said the cuts to research are disturbing. "For God's sake, we lead the world in medical research. Why would we walk away from it?" Durbin said. Copy the Story Link
Yahoo
3 hours ago
- Yahoo
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG ("Philochem'), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. ('RayzeBio'), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation in a company-sponsored Phase I trial (NCT06840535). Initial data from the first cohort of patients evaluated with the OncoACP3 diagnostic has been promising, displaying selective tumour uptake and long residence time with minimal healthy tissue uptake. IND-enabling activities to support the application for a Phase I therapeutic study with 225Ac-OncoACP3 are ongoing. Prof. Dr. Dario Neri, CEO and CSO of Philogen, commented: 'We are delighted to enter into this new collaboration with RayzeBio, a leader in the field of radiopharmaceutical medicines. This partnership will focus on the development and commercialization of OncoACP3 for both diagnostic and therapeutic applications in prostate cancer. OncoACP3 is a best-in-class targeting agent with the potential to become a breakthrough treatment in this field. This collaboration reflects our shared commitment to translating scientific innovation into meaningful clinical solutions, making OncoACP3 therapies widely available to patients in need.' Ben Hickey, President, RayzeBio commented: 'This collaboration with Philochem enhances our leadership in the rapidly advancing radiopharmaceuticals space, consistent with our strategy to bring forward best-in-class RPT candidates. OncoACP3, with its initial encouraging safety profile, provides a differentiated entry for Bristol Myers Squibb and RayzeBio into the prostate cancer arena, building on our leadership in actinium-based RPT development. This agreement is a significant milestone for RayzeBio and our goal to deliver radiopharmaceuticals to patients.' Under the terms of the agreement, Philochem will receive an up-front payment of $350m and up to $1.0bn in development, regulatory and commercial milestones. The company will also receive mid-single to low double-digit royalties payable on Global Net Sales of both Therapeutic and Diagnostic agents of OncoACP3. The closing of the transaction is subject to regulatory approvals and other customary closing conditions. The parties expect that the agreement will close in the third quarter of 2025. For Philochem, Centerview Partners UK LLP is acting as exclusive financial advisor and Cooley LLP is acting as exclusive legal counsel. About Philogen group Philogen is an Italian-Swiss group active in the biotechnology sector, specialised in the research and development of pharmaceutical products for the treatment of highly lethal diseases. Philogen's mission is to discover, develop and market innovative pharmaceuticals for the treatment of diseases of high unmet need. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights. Although the Group's drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. FOR MORE INFORMATION Philogen - Investor Relations IR@ - Emanuele Puca | Investor RelationsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
